Compare ALTO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTO | TLSI |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.7M | 270.2M |
| IPO Year | 2005 | 2020 |
| Metric | ALTO | TLSI |
|---|---|---|
| Price | $3.73 | $4.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.1M | 231.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $917,927,000.00 | $45,151,000.00 |
| Revenue This Year | $6.66 | $35.45 |
| Revenue Next Year | $0.43 | $37.58 |
| P/E Ratio | $18.70 | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $0.99 | $2.20 |
| 52 Week High | $6.11 | $7.95 |
| Indicator | ALTO | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 35.40 |
| Support Level | $2.39 | $4.28 |
| Resistance Level | $4.17 | $4.47 |
| Average True Range (ATR) | 0.14 | 0.36 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 13.27 | 2.32 |
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.